A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
ConditionMalaria, Falciparum
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-60
SponsorGlaxoSmithKline
About this trial
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
Eligibility criteria
Qualifiers
Participant must be 18 to 60 years of age inclusive, at the time of signing the informed consent.
Participants who are considered healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac assessment.
A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or
Disqualifiers
ALT (Alanine transaminase) and AST (Aspartate transaminase) within the normal range at screening.
Total bilirubin within the normal range unless the participant is known to have Gilbert's syndrome.
Body weight ≥50kg, and BMI within the range 19 to 32 kilogram per square metre (kg/m²) inclusive.
Male participants and female participants who are not of child bearing potential.
Trial design
Treatments tested in this trial
- GSK4024484C
- Placebo
Treatment groups
156 Participants
are divided into 15 treatment groups15
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov